Quoted: “We know that the rates of local recurrence after BCS are declining, which could be attributable to our improved radiation techniques and the increased use of systemic therapy, including both targeted therapy and endocrine therapy. We also know that there is a variation in the rates of local recurrence by receptor status,” said Heather Neuman, MD, MS, an associate professor at the University of Wisconsin–Madison School of Medicine and Public Health.
Office of Strategic Communication